腾讯参投富途控股配售料集资3.2亿美元 扩孖展业务
由腾讯(00700.HK)持股达33%、在美国纳斯达克交易所上市的线上证券交易商富途控股(FUTU.US)配发950万股新美国预托证券(ADS),以上日收市价计每ADS单位33.91美元计,料集资3.22亿美元,主要用於扩大证券孖展业务。
本年至今富途控股累升逾两倍,8月6日高见每股40.99美元,属2019年3月上市以来最高。截至6月底止,其近95.5万已注册用户中,约32%属付费用户。
另有30天期,最多142.5万股的超额配股权授予联席簿记人,包括高盛、瑞信、海通国际及瑞银,以照顾投资者额外需求。每股ADS相当於8股A类普通股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.